ARTICLE: Two-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia: A Small Uncontrolled Trial
AUTHORS: Niraj M Desai, Sherry G Leung, Jennifer D Motter, Dorry L Segev, Daniel Warren, Christine M Durand
JOURNAL: Ann Intern Med. 2023 Nov 28. doi: 10.7326/M23-2682. Online ahead of print.
Abstract
Background: The use of organs from donors with hepatitis C virus (HCV) viremia for recipients without HCV viremia (HCV D+/R−) with direct-acting antiviral (DAA) prophylaxis can increase access to kidney transplant (KT). However, the optimal duration of prophylaxis is unknown.
Objective: To investigate the safety and efficacy of 2-week DAA prophylaxis for HCV D+/R− KT (ClincalTrials.gov: NCT04575896).
Methods and Findings: We performed a small uncontrolled trial of 10 HCV D+/R− KTs at Johns Hopkins, approved by the institutional review board. Eligible candidates were aged 18 years or older, had negative HCV RNA results, and were without HIV or active hepatitis B. Prior organ transplant was allowed. Eligible deceased donors were aged 13 to 60 years, had positive HCV RNA results, had terminal creatinine less than 884 μmol/L (<10 mg/dL), and had no chronic changes on renal biopsy.
For the full article, click here.
For a link to the abstract, click here.
Medpage Today: Two-Week Prophylaxis May Prevent Hep C After Kidney Transplant
